Romidepsin is a bicyclic class 1 selective HDAC inhibitor approved by the FDA for treatment in patients with R/R PTCL who have failed at least one prior systemic therapy. The gene discussed is HDAC9; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.